Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation-MedSci.cn

Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation

Li, CH; Nie, W; Guo, JD; Xiong, AN; Zhong, H; Chu, TQ; Zhong, RB; Xu, JL; Lu, J; Zheng, XX; Zhang, B; Shen, YC; Pan, F; Han, BH; Zhang, XY

Han, BH; Zhang, XY (corresponding author), Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Pulm, 241 Huaihai West Rd, Shanghai 200030, Peoples R China.

Abstract

Background This study was designed to investigate the difference between brain metastases (BM) and non-brain metastases (non-BM) treated by osimertini......

Full Text Link

Links

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation

科室

工具

服务